Correction: Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial (The Lancet Oncology (2017) 18(11) (1493–1501)(S1470204517306241)(10.1016/S1470-2045(17)30624-1));Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial

The Lancet Oncology

Volumn 18, Issue 11, 2017, Pages 1493-1501

  Tawbi, Hussein A ^a   Burgess, Melissa ^b   Bolejack, Vanessa ^c   Van Tine, Brian A ^d   Schuetze, Scott M ^e   Hu, James ^f   D'Angelo, Sandra ^g   Attia, Steven ^h   Riedel, Richard F ⁱ   Priebat, Dennis A ^j   Movva, Sujana ^k   Davis, Lara E ^l   Okuno, Scott H ^h   Reed, Damon R ^m   Crowley, John ^c   Butterfield, Lisa H ^b   Salazar, Ruth ^a   Rodriguez Canales, Jaime ^a   Lazar, Alexander J ^a   Wistuba, Ignacio I ^a   Baker, Laurence H ^e   Maki, Robert G ⁿ   Reinke, Denise ^o   Patel, Shreyaskumar ^a   more..

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c USA   (United States)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF MICHIGAN   (United States)

^f UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^g MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^h MAYO CLINIC   (United States)

ⁱ DUKE UNIVERSITY   (United States)

^j WASHINGTON CANCER INSTITUTE   (United States)

^k FOX CHASE CANCER CENTER   (United States)

^l OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^m H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

ⁿ DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

^o Sarcoma Alliance for Research Through Collaboration (SARC)   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PEMBROLIZUMAB; MONOCLONAL ANTIBODY;

ADRENAL INSUFFICIENCY; ADULT; ADVANCED CANCER; ARTICLE; BONE PAIN; CLINICAL PRACTICE; CLINICAL PROTOCOL; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; HUMAN TISSUE; HYPOXIA; IMMUNOGENICITY; INFECTIOUS PNEUMONIA; INTERSTITIAL NEPHRITIS; LUNG EMBOLISM; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OSTEOSARCOMA; PARTIAL THROMBOPLASTIN TIME; PHASE 2 CLINICAL TRIAL; PLEURA EFFUSION; PNEUMONIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; SOFT TISSUE SARCOMA; THROMBOCYTE COUNT; TREATMENT RESPONSE; TUMOR BIOPSY; AGED; BONE TUMOR; CANCER STAGING; CLINICAL TRIAL; CONFIDENCE INTERVAL; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; KAPLAN MEIER METHOD; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MORTALITY; PATHOLOGY; PATIENT SAFETY; PROGNOSIS; SARCOMA; SOFT TISSUE TUMOR; STATISTICS AND NUMERICAL DATA; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR INVASION; UNITED STATES; UNIVERSITY HOSPITAL;

ACADEMIC MEDICAL CENTERS; ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; BONE NEOPLASMS; CONFIDENCE INTERVALS; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; KAPLAN-MEIER ESTIMATE; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PATIENT SAFETY; PROGNOSIS; SARCOMA; SOFT TISSUE NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; UNITED STATES;

EID: 85030654856     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(17)30864-1     Document Type: Erratum

References (39)

1. Goldblum, JR, Folpe, AL, Weiss, SW, Enzinger, FM, Weiss, SW, Enzinger and Weiss's soft tissue tumors, 6th edn., 2014, Saunders, Philadelphia, PA, 1155.
2. Savina, M, Le Cesne, A, Blay, JY, et al. Patterns of care and outcomes of patients with metastatic soft tissue sarcoma in a real-life setting: the METASARC observational study. BMC Med, 15, 2017, 78.
3. Verma, V, Denniston, KA, Lin, CJ, Lin, C, A comparison of pediatric vs. adult patients with the Ewing sarcoma family of tumors. Front Oncol, 7, 2017, 82.
4. Geller, DS, Gorlick, R, Osteosarcoma: a review of diagnosis, management, and treatment strategies. Clin Adv Hematol Oncol 8 (2010), 705–718.
5. Demetri, GD, von Mehren, M, Jones, RL, et al. Efficacy and safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional chemotherapy: results of a phase III randomized multicenter clinical trial. J Clin Oncol 34 (2016), 786–793.
6. Schoffski, P, Chawla, S, Maki, RG, et al. Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial. Lancet 387 (2016), 1629–1637.
7. Tap, WD, Jones, RL, Van Tine, BA, et al. Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial. Lancet 388 (2016), 488–497.
8. van der Graaf, WT, Blay, JY, Chawla, SP, et al., for the EORTC Soft Tissue and Bone Sarcoma Group and the PALETTE study group. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 379 (2012), 1879–1886.
9. Chou, AJ, Kleinerman, ES, Krailo, MD, et al., for the Children's Oncology Group. Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma: a report from the Children's Oncology Group. Cancer 115 (2009), 5339–5348.
10. Herbst, RS, Baas, P, Kim, DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 387 (2016), 1540–1550.
11. Plimack, ER, Bellmunt, J, Gupta, S, et al. Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study. Lancet Oncol 18 (2017), 212–220.
12. Nghiem, PT, Bhatia, S, Lipson, EJ, et al. PD-1 blockade with pembrolizumab in advanced merkel-cell carcinoma. N Engl J Med 374 (2016), 2542–2552.
13. Chen, R, Zinzani, PL, Fanale, MA, et al., for KEYNOTE-087. Phase II study of the efficacy and safety of pembrolizumab for relapsed/refractory classic Hodgkin lymphoma. J Clin Oncol 35 (2017), 2125–2132.
14. Hamid, O, Robert, C, Daud, A, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 369 (2013), 134–144.
15. Carvajal, R, Agulnik, M, Ryan, CW, et al. Trivalent ganglioside vaccine and immunologic adjuvant versus adjuvant alone in metastatic sarcoma patients rendered disease-free by surgery: a randomized phase 2 trial. Proc Am Soc Clin Oncol, 32(suppl), 2014, 5s.
16. Rosenberg, SA, Lotze, MT, Yang, JC, et al. Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg 210 (1989), 474–484.
17. Bielack, SS, Smeland, S, Whelan, JS, et al. Methotrexate, doxorubicin, and cisplatin (MAP) plus maintenance pegylated interferon alfa-2b versus MAP alone in patients with resectable high-grade osteosarcoma and good histologic response to preoperative MAP: first results of the EURAMOS-1 good response randomized controlled trial. J Clin Oncol 33 (2015), 2279–2287.
18. Van Glabbeke, M, Verweij, J, Judson, I, Nielsen, OS, Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas. Eur J Cancer 38 (2002), 543–549.
19. Kaplan, EL, Meier, P, Nonparametric-estimation from incomplete observations. J Am Stat Assoc 53 (1958), 457–481.
20. Brookmeyer, R, Crowley, J, A confidence-interval for the median survival-time. Biometrics 38 (1982), 29–41.
21. D'Angelo, SP, Shoushtari, AN, Agaram, NP, et al. Prevalence of tumor-infiltrating lymphocytes and PD-L1 expression in the soft tissue sarcoma microenvironment. Hum Pathol 46 (2015), 357–365.
22. Kim, JR, Moon, YJ, Kwon, KS, et al. Tumor infiltrating PD1-positive lymphocytes and the expression of PD-L1 predict poor prognosis of soft tissue sarcomas. PLoS One, 8, 2013, e82870.
23. Kim, C, Kim, EK, Jung, H, et al. Prognostic implications of PD-L1 expression in patients with soft tissue sarcoma. BMC Cancer, 16, 2016, 434.
24. Gajewski, TF, The next hurdle in cancer immunotherapy: overcoming the non-T-cell-inflamed tumor microenvironment. Semin Oncol 42 (2015), 663–671.
25. Bertucci, F, Finetti, P, Perrot, D, et al. PDL1 expression is a poor-prognosis factor in soft-tissue sarcomas. Oncoimmunology, 6, 2017, e1278100.
26. Ben-Ami, E, Barysauskas, CM, Solomon, S, et al. Immunotherapy with single agent nivolumab for advanced leiomyosarcoma of the uterus: results of a phase 2 study. Cancer, 2017 published online April 25. DOI:10.1002/cncr.30738.
27. George, S, Miao, D, Demetri, GD, et al. Loss of PTEN is associated with resistance to anti-PD-1 checkpoint blockade therapy in metastatic uterine leiomyosarcoma. Immunity 46 (2017), 197–204.
28. Robbins, PF, Morgan, RA, Feldman, SA, et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol 29 (2011), 917–924.
29. Maki, RG, Jungbluth, AA, Gnjatic, S, et al. A pilot study of anti-CTLA4 antibody ipilimumab in patients with synovial sarcoma. Sarcoma, 2013, 2013, 168145.
30. Shen, JK, Cote, GM, Choy, E, et al. Programmed cell death ligand 1 expression in osteosarcoma. Cancer Immunol Res 2 (2014), 690–698.
31. Tsukahara, T, Kawaguchi, S, Torigoe, T, et al. Prognostic significance of HLA class I expression in osteosarcoma defined by anti-pan HLA class I monoclonal antibody, EMR8-5. Cancer Sci 97 (2006), 1374–1380.
32. Mechtersheimer, G, Staudter, M, Majdic, O, Dorken, B, Moldenhauer, G, Moller, P, Expression of HLA-A,B,C, beta 2-microglobulin (beta 2m), HLA-DR, -DP, -DQ and of HLA-D-associated invariant chain (Ii) in soft-tissue tumors. Int J Cancer 46 (1990), 813–823.
33. Kleinerman, ES, Jia, SF, Griffin, J, Seibel, NL, Benjamin, RS, Jaffe, N, Phase II study of liposomal muramyl tripeptide in osteosarcoma: the cytokine cascade and monocyte activation following administration. J Clin Oncol 10 (1992), 1310–1316.
34. Brinkrolf, P, Landmeier, S, Altvater, B, et al. A high proportion of bone marrow T cells with regulatory phenotype (CD4+CD25hiFoxP3+) in Ewing sarcoma patients is associated with metastatic disease. Int J Cancer 125 (2009), 879–886.
35. Berghuis, D, Santos, SJ, Baelde, HJ, et al. Pro-inflammatory chemokine-chemokine receptor interactions within the Ewing sarcoma microenvironment determine CD8(+) T-lymphocyte infiltration and affect tumour progression. J Pathol 223 (2011), 347–357.
36. Paoluzzi, L, Cacavio, A, Ghesani, M, et al. Response to anti-PD1 therapy with nivolumab in metastatic sarcomas. Clin Sarcoma Res, 6, 2016, 24.
37. Italiano, A, Le Cesne, A, Bellera, C, et al. GDC-0449 in patients with advanced chondrosarcomas: a French Sarcoma Group/US and French National Cancer Institute Single-Arm Phase II Collaborative Study. Ann Oncol 24 (2013), 2922–2926.
38. Kostine, M, Cleven, AH, de Miranda, NF, Italiano, A, Cleton-Jansen, AM, Bovee, JV, Analysis of PD-L1, T-cell infiltrate and HLA expression in chondrosarcoma indicates potential for response to immunotherapy specifically in the dedifferentiated subtype. Mod Pathol 29 (2016), 1028–1037.
39. Postow, MA, Callahan, MK, Barker, CA, et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med 366 (2012), 925–931.